Patent · US Active

Means and methods for the treatment of angiogenesis-, fibrosis- and cancer-related diseases with protein oligomers comprising NC-1-Fc

US11845784B2 · kind B2 · utility

0Cited by

4References

3Claims

0Family size

Assignee

Heidelberg Biotech GmbH · DE

Inventors

Kashi Javaherian · Heidelberg, DE
Jürgen Debus · Heidelberg, DE
Amir Abdollahi · Heidelberg, DE

Key dates

Filing date	Apr 16, 2019
Grant date	Dec 19, 2023
Priority date	—
Expiry date	Feb 29, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention pertains to a method for producing a protein oligomer comprising at least two, and preferably three heterodimeric human NC-I-Fc proteins, the method comprising: a) culturing a host cell expressing (i) a fusion protein comprising, from N- to C-terminus, human NC-1 from collagen 18 fused to human IgGI Fc with “knob” mutations, or human IgGI Fc with “knob” mutations fused to human NC-1 from collagen 18, and (ii) human IgGI Fc with “hole” mutations, under conditions which allow the formation of a protein oligomer comprising at least two, and preferably three heterodimeric human NC-1-Fc proteins, and wherein the fusion protein of (i) and the human IgGI Fc with “hole” mutations of (ii) are expressed in a ratio of 2:1 or higher, and b) obtaining the protein oligomer comprising at least two, and preferably three heterodimeric human NC-1-Fc proteins.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.